Trials / Recruiting
RecruitingNCT06433752
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | No Intervention |
Timeline
- Start date
- 2024-07-22
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2024-05-30
- Last updated
- 2026-04-07
Locations
85 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06433752. Inclusion in this directory is not an endorsement.